Freeline Therapeutics Holdings plc announced that Jan Thirkettle, Ph.D., Chief Development Officer, has decided to leave Freeline to pursue a new opportunity. Dr. Thirkettle will continue in his current role until June 30, 2021, to ensure a smooth transition of his responsibilities. The Company has begun an external search for Dr. Thirkettle’s replacement.